CHAPEL HILL - NanoCor Therapeutics, a Chapel Hill startup, got a $3.75 million investment from medical-device giant Medtronic to work on a gene-therapy-based treatment for congestive heart failure. If preclinical tests are successful, Medtronic has agreed to invest at least an additional $3.75 million to start tests in humans.